Forkortelser: BID: twice a day; BSA: Body Surface Area; PASI: psoriasis area and severity index; POETYK-PSO: Program fOr Evaluation of TYK2 inhibitor psoriasis; sPGA: Static Physicians Global Assessment; ss PGA skalp-specifik Physicians Global Assessment; QD: once daily én gang daglig.
Referanser:
1. Sotyktu SPC 20.12.2023
2. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety result from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PS0-1 trial. J Am Acad Dermatol. 2023;88(1):29-39.
3. Strober B, Tha i D, Solen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40-51.
4. European Public Assessment Report (EPAR) for SOTYKTU 31.3.2023
5. Crowley JJ. Challenges in Psoriasis Treatment: Nail, Scalp, and Palmoplantar lnvolvement. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham.